AHA 2024丨详细日程一览！8场最新科学研究专场，29项研究成果即将重磅揭晓

*本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放。

2024年美国心脏协会科学会议（AHA）将于2024年11月16日至18日在芝加哥举行，以最佳科学和心血管临床实践为特色，涵盖基础、临床、人群和转化内容的各个方面。为期3天的会议共设立了8个最新科学研究（Late Breaking Science）专场，将带来29项最新研究结果。目前官网日程已经上线，《心关注》对此进行了整理，一起先睹为快吧！

LBS.01 庆祝心血管科学百年：从预防到治疗，再到治愈

北京时间：11月16日 21:30~22:45

BPROAD - Effects of Intensive Blood Pressure Control in Patients with Type 2 Diabetes (BPROAD)
强化血压控制对2型糖尿病患者的影响：BPROAD研究SUMMIT - Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
替尔泊肽治疗合并肥胖的射血分数保留型心力衰竭患者：SUMMIT试验Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study
Nexiguran ziclumeran（nex-z，又称NTLA-2001），一种基于CRISPR的研究性体内疗法，用于治疗伴有转甲状腺素蛋白淀粉样变心肌病（ATTR-CM）的患者：1期研究中期报告

LBS.02 重新定义心律失常治疗：突破界限

北京时间：11月17日 02:30~03:45

VANISH2 - Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2)
缺血性心肌病室性心动过速的导管消融或抗心律失常药物治疗：VANISH2研究OPTION - Randomized Comparison of Left Atrial Appendage Closure with Oral Anticoagulation after Catheter Ablation for Atrial Fibrillation (OPTION)
心房颤动导管消融术后左心耳封堵与口服抗凝药的随机比较：OPTION研究BRAIN AF - Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation (BRAIN AF)
抗凝治疗预防心房颤动缺血性卒中和神经认知障碍的盲法随机试验：BRAIN AF实验

LBS.03 智能心脏病学：利用人工智能和创新改善心脏健康

北京时间：11月17日 04:15~05:30

PHARM-HF A&F - Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study)
对退伍军人事务医疗保健系统中初级保健药剂师进行随机审核和反馈以提高心衰用药优化的评估：PHARM-HF A&F研究SEISMIC HF-I - Novel AI to Assess Intracardiac Filling Pressure: The Non-invasive SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study
评估心内充盈压的新型人工智能：无创心震图在心力衰竭心血管监测中的应用研究I——SEISMIC-HF I研究AI-ECHO - Artificial Intelligence-based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial (Accepted, not confirmed at time of publication)
基于人工智能的自动超声心动图测量和超声技师的工作流程：AI-ECHO随机交叉试验（已接受，发表时尚未确认）PanEcho: Complete AI-enabled echocardiography interpretation with multi-task deep learning
利用多任务深度学习进行完整的人工智能超声心动图解读：PanEcho研究

LBS.04 从干预到预防：冠心病和瓣膜性心脏病的研究进展

北京时间：11月17日 21:00~22:15

GLORIOUS - Efficacy of Restrictive versus Liberal Oxygenation in Patients undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial (GLORIOUS)
冠状动脉旁路移植术或主动脉瓣置换术患者限制性吸氧与自由性吸氧的疗效：GLORIOUS随机临床试验Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial (GLORIOUS)
GLP-1受体激动剂对冠状动脉旁路移植术或主动脉瓣置换术患者的疗效：GLORIOUS随机临床试验ENBALV - Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early after Surgical Bioprosthetic Valve Replacement: ENBALV trial
艾多沙班在外科生物瓣膜置换术后早期抗凝治疗中的有效性和安全性：ENBALV试验The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction. The results of the spironolactone factorial.
秋水仙碱 vs. 安慰剂和螺内酯 vs. 安慰剂在心肌梗死患者中的2×2因子随机对照试验：CLEAR SYNERGY（OASIS 9）试验

LBS.05 预防创新与全球实施

北京时间：11月18日 04:30~05:45

TOPSPIN - A Three-arm Randomized Trial For Treatment Optimisation Of Blood Pressure With Single-pill Combinations In India
印度单片复方制剂优化血压治疗的三臂随机试验试验：TOPSPIN实验NUDGE-FLU - Electronic Nudges to Increase Influenza Vaccination among Patients with History of Myocardial Infarction: Insights from 3 Randomized Clinical Trials Enrolling >2 Million Patients (NUDGE-FLU)
电子助推提高心肌梗死史患者的流感疫苗接种率：来自200多万患者参与的三项随机临床试验的见解——NUDGE-FLU研究ZODIAC - Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies after Acute Coronary Syndrome (ZODIAC)
决策支持系统辅助医生优化急性冠脉综合征后早期降脂治疗的实用随机对照试验：ZODIAC实验MHYH - Preliminary Results of Randomized Trial of New Versus Reconditioned Pacemakers for Patients Unable to Obtain a New Device in Low and Middle-Income Countries: The My Heart Your Heart (MHYH) Randomized Trial
为中低收入国家无法获得新设备的患者提供新起搏器与修复起搏器的随机试验初步结果：MHYH随机试验

LBS.06 以四大支柱为基础：心力衰竭药物疗法的新试验

北京时间：11月18日 21:00~22:15

ENDEAVOR - Myeloperoxidase Inhibition with Mitiperstat in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Primary Results from the ENDEAVOR Randomized Clinical Trial
髓过氧化物酶抑制剂Mitiperstat治疗射血分数保留和轻度降低的心力衰竭：ENDEAVOR随机临床试验的主要结果SARAH - Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial – The SARAH Trial
沙库巴曲缬沙坦对接受蒽环类化疗的高危患者预防心脏毒性的影响：SARAH双盲随机安慰剂对照临床试验Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)
新型布美他尼鼻喷雾剂 (BNS) 与静脉注射和口服布美他尼相比具有安全性、耐受性和同等疗效：RSQ-777-02研究REALIZE-K - Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial
环硅酸锆钠和MRA优化治疗合并高钾血症的射血分数降低型心力衰竭：REALIZE-K随机对照试验的主要结果

LBS.07 房颤管理的革命性变革：前沿方法

北京时间：11月18日 22:45~24:00

PROMPT-AF - Comparison of Linear Ablation Plus Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results from the PROMPT-AF Randomized Trial
线性消融联合肺静脉隔离与单纯肺静脉隔离治疗持续性房颤的比较：PROMPT-AF随机试验的结果CRRF-PeAF - Cryoballoon Ablation versus Radiofrequency Ablation in Patients with Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Non-inferiority Clinical Trial
持续性心房颤动患者的冷冻球囊消融与射频消融：CRRF-PeAF 一项前瞻性、多中心、随机、非劣效性临床试验TRIM-AF - Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial
二甲双胍和改变生活方式/危险因素上游预防心房颤动进展的随机对照试验：心房颤动的针对性风险干预和二甲双胍的TRIM-AF试验ARREST-AF - Aggressive Risk factor REduction STudy for Atrial Fibrillation (ARREST-AF) implications for ablation outcomes: A Randomized Clinical Trial (Accepted, not confirmed at time of publication)
心房颤动的激进危险因素降低对消融结果的影响：ARREST-AF随机临床试验（已接受，发表时尚未确认）

LBS.08 新靶点和新疗法：脂质疗法的进展

北京时间：11月19日 02:30~03:45

ALPACAR - Phase 2 Trial of Zerlasiran: Multiple doses of a Short-Interfering RNA Targeting Lipoprotein(a) over 60 weeks
Zerlasiran的2期ALPACAR试验：在60周内多次服用靶向Lp(a)的短干扰RNAKRAKEN - A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
Muvalaplin的随机2期KRAKEN试验：口服干扰Lp(a)颗粒组装的药物BROOKLYN - Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (BROOKLYN)
Obicetrapib对杂合子家族性高胆固醇血症患者的安全性和有效性：BROOKLYN研究

《心关注》

将持续为您带来会议最新动态

敬请关注！

*本文不构成任何诊疗相关意见和建议，

仅供医疗人员参考学习

如发现文内有误请联系我们

扫码查看申明

全面工作

传播矩阵

FOLLOW US

• 苏州工业园区东方华夏心血管健康研究院

• 电话：0512-68295918

• 邮箱：info@ccahouse.org

• 网址：https://www.ccahouse.org

• 地址：苏州工业园区水坊路36号姑苏会平江馆心脏之家